Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

NCT03071965 PHASE2 COMPLETED Results posted

This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent sham surgery in the respective precursor study (NTMT-01 or NTMT-02). A substudy was conducted in which subjects enrolled in study (NTMT-02), who had 1 study-eligible eye that underwent sham surgery, were offered the option to have NT-501 implanted in the same study eye. Of the 19 subjects who had 1 study-eligible eye and underwent sham surgery in the Cohort 2 precursor study (NTMT-02), 16 subjects elected to have NT-501 implanted in the same study eye during the substudy

Details

Lead sponsor	Neurotech Pharmaceuticals
Phase	PHASE2
Status	COMPLETED
Enrolment	70
Start date	Fri May 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue May 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• MacTel (Macular Telangiectasia) Type 2

Interventions

• Ciliary neurotrophic factor (CNTF)
• Surgery
• Surgery

Countries

United States, Australia